Pfizer's Xeljanz gets FDA nod as joint disease treatment

(Reuters) - U.S. drugmaker Pfizer Inc said on Thursday the United States Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for the treatment of a joint disease.